Free tool
FAERS Monitor: Namzaric
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206439 or its brand name (Namzaric, Donepezil Hydrochloride, Memantine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
608
Serious
261
43% of reports
Hospitalization
117
Death reported
72
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death58
- dizziness58
- confusional state48
- drug ineffective42
- fall42
- hallucination38
- fatigue37
- diarrhoea36
- nausea33
- vomiting32
- off label use26
- malaise23
- decreased appetite21
- condition aggravated19
- asthenia18
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 9 |
| 2016 | 50 |
| 2017 | 156 |
| 2018 | 76 |
| 2019 | 99 |
| 2020 | 73 |
| 2021 | 43 |
| 2022 | 32 |
| 2023 | 23 |
| 2024 | 23 |
| 2025 | 16 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,551 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hallucinationSignal | 38 | 17.5 | 12.8 | 575 |
| confusional stateSignal | 48 | 10.3 | 7.8 | 396 |
| fallSignal | 42 | 4.4 | 3.3 | 107 |
| dizzinessSignal | 58 | 4.0 | 3.1 | 132 |
| decreased appetiteSignal | 21 | 3.1 | 2.1 | 29 |
| vomitingSignal | 32 | 2.4 | 1.7 | 24 |
| deathSignal | 58 | 2.3 | 1.8 | 44 |
| condition aggravatedSignal | 19 | 2.2 | 1.4 | 11 |
| diarrhoea | 36 | 1.9 | 1.4 | 16 |
| malaise | 23 | 1.8 | 1.2 | 8 |
| asthenia | 18 | 1.7 | 1.1 | 4 |
| fatigue | 37 | 1.6 | 1.2 | 9 |
| nausea | 33 | 1.4 | 1.0 | 4 |
| drug ineffective | 42 | 1.1 | 0.8 | 0 |
| off label use | 26 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.